直接抗病毒药物时代特殊人群HCV感染的管理和治疗

李俊利; 尚佳; 宁会彬

doi:10.3969/j.issn.1001-5256.2018.02.005

直接抗病毒药物时代特殊人群HCV感染的管理和治疗

DOI: 10.3969/j.issn.1001-5256.2018.02.005

河南省人民医院感染科

基金项目:

河南省医学科技攻关计划省部共建项目(201401015)；河南省科技厅医学科技攻关计划项目(152102310135)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2143
- HTML全文浏览量: 32
- PDF下载量: 479
- 被引次数: 0
出版历程
- 出版日期: 2018-02-20

Management and treatment of special populations with hepatitis C virus infection in the era of direct-acting antiviral agents

Department of Infectious Diseases, Henan Provincial People′s Hospital

Research funding:

摘要

摘要:
慢性丙型肝炎呈全球性流行,不同性别、年龄、种族、民族人群均易感染HCV。分别阐述了儿童丙型肝炎患者、合并肾损伤患者、肝移植患者、合并肝硬化患者、合并HIV感染者、急性丙型肝炎患者等不同特殊人群HCV感染的管理方法和个体化治疗方案。
- 肝炎病毒属 /
- 肝炎,丙型,慢性 /
- 疾病管理 /
- 治疗
Abstract:
Chronic Hepatitis C is a global epidemic, and people with different sexes, ages, races, and nationalities are susceptible to hepatitis C virus (HCV) infection.This article elaborates on the management method and individualized treatment regimens for special populations, including children with hepatitis C, patients with renal injury, patients undergoing liver transplantation, patients with liver cirrhosis, patients with HIV infection, and patients with acute hepatitis C.
- hepacivirus /
- hepatitis C, chronic /
- disease management /
- therapy

HTML全文

参考文献(30)

[1]GESSONI G, MANONI F.Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area:a seroepidemiological study[J].Eur J Med, 1993, 2 (2) :79-82.

[2]GOODMAN ZD, MAKHLOUF HR, LIU L, et al.Pathology of chronic hepatitis C in children:liver biopsy findings in the PedsC Trial[J].Hepatology, 2008, 47 (3) :836-843.

[3]ZHU SS, ZENG QL, DONG Y, et al.Interferon-αplus ribavirin yields98%sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C[J].Hepatol Int, 2015, 9 (4) :578-585.

[4]PUOTI C, GUARISCO R, BELLIS L, et al.Diagnosis, management, and treatment of hepatitis C:an update[J].Hepatology, 2009, 50 (1) :322.

[5]KONG D, WU D, WANG T, et al.Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection[J].Int J Infect Dis, 2013, 17 (7) :535-538.

[6]LIDAR M, LIPSCHITZ N, AGMON-LEVIN N, et al.Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia[J].Clin Rev Allergy Immunol, 2012, 42 (2) :238-246.

[7]CORNPROPST M, DENNING J, CLEMONS D, et al.The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977[J].J Hepatol, 2012, 56 (1) :s433-s433.

[8]KWO PY, BADSHAH MB.New hepatitis C virus therapies:drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renel disease[J].Curr Opin Organ Transplant, 2015, 20 (3) :235-241.

[9]SUDA G, FURUSYO N, TOYODA H, et al.Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection:a nationwide retrospective study in Japan[J].J Gastroenterol, 2018, 53 (1) :119-128.

[10]TANEJA S, DUSEJA A, de A, et al.Successful treatment of chronic hepatitis C infection with directly acting antivirals in renaltransplant recipients[J].Nephrology (Cariton) , 2017.[Epub ahead of print]

[11]BRIZI F, DIXIT V, MESSA P, et al.Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients:metaanalysis of clinical studies[J].J Viral Hepat, 2014, 21 (10) :681-689.

[12]CARBONE M, LENCI I, BAIOCCHI L.Prevention of hepatitis C recurrence after liver transplantation:an update[J].World J Gastrointest Pharmacol Ther, 2012, 3 (4) :36-48.

[13]AKAMATSU N, SUGAWARA Y.Liver transplantation and hepatitis C[J].Int J Hepatol, 2012, 2012:686135.

[14]PASCASIO JM, VINAIXA C, FERRER MT, et al.Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation[J].J Hepatol, 67 (6) :1168-1176.

[15]ZEUZEM S, MENSA FJ.Concordance between SVR12 and SVR24in genotype 1 HCV patients receiving interferon-free treatment in the SOUND-C2 study[J].Hepatology, 2013, 58 (4) :1516.

[16]BERNUTH S, GRIMM D, VOLLMAR J, et al.Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation:a real-world cohort[J].Drug Des Devel Ther, 2017, 12 (11) :21318-21388.

[17]WILLEMSE SB, RAZAVI-SHEARER D, ZUURE FR, et al.The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms[J].Neth J Med, 2015, 73 (9) :417-431.

[18]van der MEER AJ, VELDT BJ, FELD JJ, et al.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis[J].JAMA, 2012, 308 (24) :2584-2593.

[19]ALEMAN S, RAHBIN N, WEILAND O, et al.A risk for hepatocellular carcinoma persistslong-term after sustained virologic responsein patients with hepatitis C-associated livercirrhosis[J].Clin Infect Dis, 2013, 57 (2) :230-650.

[20]ASAHINA Y, TSUCHIYA K, NISHIMURA T, et al.α-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C[J].Hepatology, 2013, 58 (4) :1253-1262.

[21]GEORGE SL, BACON BR, BRUNT EM, et al.Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy:a 5-year follow-up of 150 patients[J].Hepatology, 2009, 49 (3) :729-738.

[22]NAGAOKI Y, AIKATA H, NAKANO N, et al.Development of hepatocellular carcinoma in patients withhepatitis C virus infection who achieved sustained virologicalresponse following interferon therapy:a large-scale, long-termcohort study[J].J Gastroenterol Hepatol, 2016, 31 (5) :1009-1015.

[23]EL-SERAG HB, KANWAL F, RICHARDSON P, et al.Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection[J].Hepatology, 2016, 64 (1) :130-137.

[24]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.

[25]WIEGAND J, BUGGISCH P, BOECHER W, et al.Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection:the HEP-NET acute-HCV-II study[J].Hepatology, 2006, 43 (2) :250-256.

[26]SANTANTONIO T, FASANO M, SINISI E, et al.Efficacy of a 569 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after 570 failure of spontaneous clearance[J].J Hepatol, 2005, 42 (3) :329-333.

[27]European Association for Study of Liver.EASL Clinical Practice Guidelines:management of 445 hepatitis C virus infection[J].J Hepatol, 2014, 60 (2) :392-420.

[28]SANTANTONIO T, FASANO M, SAGNELLI E, et al.Acute hepatitis C:a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin[J].Hepatology, 2014, 59 (6) :2101-2109.

[29]JAMALIDOUST M, NAMAYANDEH M, MOGHADAMI M, et al.Comparison of HCV viral load and its genotype distributions in HCV mono-and HIV/HCV co-infected illicit drug users[J].Virol J, 2017, 14 (1) :127.

[30]NEUKAM K, MORANO-AMADO LE, RIVERO-JUAREZ A, et al.HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals:a prospective cohort study[J].HIV Clin Trials, 2017, 18 (3) :126-134.

施引文献

资源附件(0)

访问统计